Senstend

RSS

lidocaine / prilocaine

Authorised
This medicine is authorised for use in the European Union.

Overview

Senstend is a medicine containing the active substances lidocaine and prilocaine. It is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration).

This medicine is the same as Fortacin, which is already authorised in the EU. The company that makes Fortacin has agreed that its scientific data can be used for Senstend (‘informed consent’).

This EPAR was last updated on 29/11/2019

Authorisation details

Product details
Name
Senstend
Agency product number
EMEA/H/C/005298
Active substance
  • lidocaine
  • prilocaine
International non-proprietary name (INN) or common name
lidocaine / prilocaine
Therapeutic area (MeSH)
Premature Ejaculation
Anatomical therapeutic chemical (ATC) code
N01BB20
Publication details
Marketing-authorisation holder
Plethora Pharma Solutions Limited
Date of issue of marketing authorisation valid throughout the European Union
14/11/2019
Contact address

32 Merrion Street
Upper Dublin 2
Ireland

Product information

14/11/2019 Senstend - EMEA/H/C/005298 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANESTHETICS

Therapeutic indication

Senstend is indicated for the treatment of primary premature ejaculation in adult men.

Assessment history

How useful was this page?

Add your rating